Cerebral palsy is the most prevalent physical disability in children; however, its inherent molecular mechanisms remain unclear. In the present study, we performed in-depth clinical and molecular analysis on 120 idiopathic
cerebral palsy families, and identified underlying detrimental genetic variants in 45% of these patients. In addition to germline variants, we found disease-related postzygotic mutations in ∼6.7% of
cerebral palsy patients. We found that patients with more severe motor impairments or a comorbidity of
intellectual disability had a significantly higher chance of harbouring disease-related variants. By a compilation of 114 known
cerebral-palsy-related genes, we identified characteristic features in terms of inheritance and function, from which we proposed a dichotomous classification system according to the expression patterns of these genes and associated
cognitive impairments. In two patients with both
cerebral palsy and
intellectual disability, we revealed that the defective TYW1, a
tRNA hypermodification
enzyme, caused primary
microcephaly and problems in motion and cognition by hindering neuronal proliferation and migration. Furthermore, we developed an algorithm and demonstrated in mouse brains that this malfunctioning hypermodification specifically perturbed the translation of a subset of
proteins involved in cell cycling. This finding provided a novel and interesting mechanism for congenital
microcephaly. In another
cerebral palsy patient with normal intelligence, we identified a mitochondrial
enzyme GPAM, the hypomorphic form of which led to hypomyelination of the corticospinal tract in both human and mouse models. In addition, we confirmed that the aberrant Gpam in mice perturbed the lipid metabolism in astrocytes, resulting in suppressed astrocytic proliferation and a shortage of
lipid contents supplied for oligodendrocytic myelination. Taken together, our findings elucidate novel aspects of the aetiology of
cerebral palsy and provide insights for future therapeutic strategies.